BTSA1.2 Datasheet | DC59120

BTSA1.2 — Datasheet

CAT. NO. DC59120

Parameter	Value
Chemical Name	3H -Pyrazol-3-one, 4-[2-(4,5-dimethyl-2-thiazolyl)diazenyl]-2,4-dihydro-5-phenyl-2-(4-phenyl-2-thiazolyl)- (ACI)
CAS No.	2254256-66-9
Formula	C23H18N6OS2
M.Wt	458.56
SMILES	O=C1N(N=C(C=2C=CC=CC2)C1N=NC3=NC(=C(S3)C)C)C4=NC(=CS4)C=5C=CC=CC5
Purity	>98%
Storage	-20

Biological Activity

BTSA1.2 is a rationalized BTSA1 analog with improved binding to BAX, cellular cytotoxicity, and better toleratence in vivo. Combination of BTSA1.2 with Navitoclax demonstrates synergistic efficacy in apoptosis-resistant cancer cells, xenografts, and patient-derived tumors while sparing healthy tissues.

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

Target

BAX

References & source

[1] Promising approach against treatment-resistant cancer. Retrieved Mar 8th, 2022 from https://medicalxpress.com/news/2022-03-approach-treatment-resistant-cancer.html

[2] Andrea Lopez et al, Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer, Nature Communications (2022). DOI: 10.1038/s41467-022-28741-7

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.